BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25604610)

  • 1. Treatment initiation factors and cognitive outcome in youth with perinatally acquired HIV infection.
    Lazarus JR; Rutstein RM; Lowenthal ED
    HIV Med; 2015 Jul; 16(6):355-61. PubMed ID: 25604610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor cognitive functioning of school-aged children in thailand with perinatally acquired HIV infection taking antiretroviral therapy.
    Puthanakit T; Aurpibul L; Louthrenoo O; Tapanya P; Nadsasarn R; Insee-ard S; Sirisanthana V
    AIDS Patient Care STDS; 2010 Mar; 24(3):141-6. PubMed ID: 20214481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation?
    Newell ML; Patel D; Goetghebuer T; Thorne C;
    J Infect Dis; 2006 Apr; 193(7):954-62. PubMed ID: 16518757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India.
    Banerjee T; Pensi T; Banerjee D; Grover G
    Ann Trop Paediatr; 2010; 30(1):27-37. PubMed ID: 20196931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
    Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
    Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Jun; 46(11):1751-60. PubMed ID: 18426371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurocognitive function profile in HIV-infected school-age children.
    Koekkoek S; de Sonneville LM; Wolfs TF; Licht R; Geelen SP
    Eur J Paediatr Neurol; 2008 Jul; 12(4):290-7. PubMed ID: 17950012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1.
    Patel K; Van Dyke RB; Mittleman MA; Colan SD; Oleske JM; Seage GR;
    AIDS; 2012 Oct; 26(16):2027-37. PubMed ID: 22781228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women.
    Kowalska A; Niemiec T; El Midaoui A; Burkacka E
    Med Wieku Rozwoj; 2003; 7(4 Pt 1):459-68. PubMed ID: 15010556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.